Ortho Clinical Diagnostics Presents Cardiac Advances at EuroMedLab 2019
|
By LabMedica International staff writers Posted on 20 May 2019 |

Image: The Multi-Test VITROS chemistry product slides (Photo courtesy of Ortho Clinical Diagnostics).
Ortho Clinical Diagnostics (Raritan, NJ, USA) sponsored an educational workshop on high-sensitivity troponin assays and presented five scientific posters at EuroMedLab 2019, the 23rd IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine, which took place from May 19-23, 2019, at the CCIB - Centre Convencions Internacional in Barcelona. Ortho also displayed its new multi-test VITROS Chemistry Product Slides, the VITROS Cell, a compact automation solution allowing two VITROS XT 7600 instruments (launched in 2018) to operate as a seamless solution, and the VITROS XT 7600 Integrated System at its booth during the congress.
Ortho, an in vitro diagnostics company serving the clinical laboratory and immunohematology communities, offers sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho's high-quality products and services enable health care professionals to make better-informed treatment decisions across hospitals, hospital networks, blood banks and labs in more than 125 countries and territories.
In addition to the educational workshop, "The Clinical Use and Performance of High-Sensitivity Troponin Assays with the Esc 0-1 Algorithm: Overcoming Challenges in Implementation," Ortho presented the following five scientific posters at EuroMedLab:
- Evaluation of the New Multi-Test VITROS Chemistry Product Slides on the VITROS XT 7600 Integrated System
- Sigma Metrics for Assessing the Analytical Quality of the New Multi-Test VITROS XT Chemistry Products Slides
- Precision of the New Multi-Test VITROS Chemistry Product Slides on the VITROS XT 7600 Integrated System
- Performance Evaluation of the VITROS hs Troponin I Assay on the VITROS ECi/ECiQ and 3600 Immunodiagnostic and VITROS 5600/XT 7600 Integrated Systems
- Performance Evaluation of the VITROS Immunodiagnostic Products B·R·A·H·M·S PCT Assay on the VITROS 3600 Immunodiagnostic System
"Ortho is committed to staying ahead of the rapidly evolving clinical lab environment," said Joan Martin, executive vice president and head of Ortho's EMEA region." At this year's EuroMedLab, we're proud to be presenting data on two of our just-launched, key product offerings: our new high-sensitivity troponin assay and Ortho's VITROS XT MicroSlide. The XT MicroSlide can perform two tests simultaneously to improve lab workflow performance, productivity and clinical outcomes."
Ortho, an in vitro diagnostics company serving the clinical laboratory and immunohematology communities, offers sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho's high-quality products and services enable health care professionals to make better-informed treatment decisions across hospitals, hospital networks, blood banks and labs in more than 125 countries and territories.
In addition to the educational workshop, "The Clinical Use and Performance of High-Sensitivity Troponin Assays with the Esc 0-1 Algorithm: Overcoming Challenges in Implementation," Ortho presented the following five scientific posters at EuroMedLab:
- Evaluation of the New Multi-Test VITROS Chemistry Product Slides on the VITROS XT 7600 Integrated System
- Sigma Metrics for Assessing the Analytical Quality of the New Multi-Test VITROS XT Chemistry Products Slides
- Precision of the New Multi-Test VITROS Chemistry Product Slides on the VITROS XT 7600 Integrated System
- Performance Evaluation of the VITROS hs Troponin I Assay on the VITROS ECi/ECiQ and 3600 Immunodiagnostic and VITROS 5600/XT 7600 Integrated Systems
- Performance Evaluation of the VITROS Immunodiagnostic Products B·R·A·H·M·S PCT Assay on the VITROS 3600 Immunodiagnostic System
"Ortho is committed to staying ahead of the rapidly evolving clinical lab environment," said Joan Martin, executive vice president and head of Ortho's EMEA region." At this year's EuroMedLab, we're proud to be presenting data on two of our just-launched, key product offerings: our new high-sensitivity troponin assay and Ortho's VITROS XT MicroSlide. The XT MicroSlide can perform two tests simultaneously to improve lab workflow performance, productivity and clinical outcomes."
Latest Industry News
- Integrated DNA Technologies Expands into Clinical Diagnostics
- Co-Diagnostics Agreement Expands Commercial and Distribution Reach in South Asia
- Automated MSI Test Gains IVDR Certification to Guide CRC Therapy
- New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network
- MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition
- Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
- Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
- QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
- WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read moreMolecular Diagnostics
view channel
First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read more
Plasma ctDNA Testing Predicts Breast Cancer Recurrence After Neoadjuvant Therapy
Accurate identification of breast cancer patients at risk of relapse after pre-surgery treatment is central to guiding adjuvant decisions, particularly in aggressive disease. Circulating fragments of tumor... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
Tuberculosis (TB) remains a leading infectious killer, with more than 3,300 deaths and 29,000 new illnesses every day. Diagnostic delays and dependence on centralized laboratory networks continue to impede... Read more
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read moreTechnology
view channel
Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
Chemotherapy selection for breast cancer is challenged by heterogeneous tumor responses. Conventional chemosensitivity assays can be slow, require large sample volumes, and struggle with complex biological... Read more








